Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 8/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4358804 | 0.79 | GPR34 (0.47) | SMPD1GAAMAPT | |
| SCHEMBL4357784 | 0.77 | MEN1 (0.61) | CYSLTR1CYSLTR2ALDH1A1MAPTCYP3A4 | |
| SCHEMBL3259834 | 0.74 | SMPD1 (0.45) | ALOX5SMPD1ALDH1A1GAA | |
| SCHEMBL31295461 | 0.73 | MGAM (0.59) | CYSLTR1CYSLTR2ALDH1A1MAPTCYP3A4 | |
| SCHEMBL4363689 | 0.73 | KDM4E (0.51) | ALDH1A1 | |
| SCHEMBL3982953 | 0.73 | NPC1 (0.54) | SMPD1ALDH1A1 | |
| SCHEMBL2942755 | 0.72 | MAP1LC3B (0.41) | SMPD1 | |
| SCHEMBL22213509 | 0.72 | SMN1; SMN2 (0.63) | CYSLTR1ALOX5ALDH1A1GAAMAPT | |
| SCHEMBL4373602 | 0.71 | CYP1A2 (0.46) | ALDH1A1 | |
| SCHEMBL4375334 | 0.70 | HDAC3 (0.41) | SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | claimed |
| US-7476686-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7094807-B2 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060014836-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | CHEN DAWEI | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014836-A1 | Substituted aryl thioureas and related compounds; inhibitors of viral replication | NAT1, PIGS, SLC10A1 | CYSLTR1 738/4885CYSLTR2 1306/4885GPBAR1 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.